News

  • 13 January 2020

    Avitide Inc., the industry leader in the discovery and development of custom affinity purification resins, announce a partnership expansion with Allergan. Under the terms of the agreement, Avitide will use its proprietary affinity chromatography discovery, development, and supply platform for programs defined by Allergan. 

  • 10 January 2020

    10 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the results of the pre-clinical and first-in-human single dose DSR proof-of-concept studies for volume overload due to heart failure have been published in the prestigious peer-reviewed journal Circulation.

  • 9 January 2020

    JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, announced it has received “Breakthrough Device” designation from the U.S. Food and Drug Administration (FDA). This designation is for severe aortic regurgitation (AR) and AR-dominant mixed aortic valve disease, a life-threatening and seriously debilitating condition, in patients at high risk for surgery. 

  • 9 January 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited revenue of approximately $10 million for the fourth quarter of 2019 as compared to $0.5 million in the prior year period. For the full year ended December 31, 2019, unaudited revenue was approximately $14 million as compared to $0.7 million for all of 2018. 

  • 7 January 2020

    Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the first-in-human repeated dose study of alfapump DSR (Direct Sodium Removal) for the treatment of diuretic-resistant heart failure patients.